Cited by 807Nanoparticle-Based Drug DeliveryIron Metabolism and DisordersRNA Interference and Gene Delivery

The transferrin receptor and the targeted delivery of therapeutic agents against cancer

Open access
Daniels, Tracy R., Bernabeu, Ezequiel, Rodríguez, José A., Patel, Shabnum, Kozman, Maggie, Chiappetta, Diego A., Holler, Eggehard, Ljubimova, Julia Y. +2 more·2012·Biochimica et Biophysica Acta (BBA) - General Subjects

Abstract

Background Traditional cancer therapy can be successful in destroying tumors, but can also cause dangerous side effects. Therefore, many targeted therapies are in development. The transferrin receptor (TfR) functions in cellular iron uptake through its interaction with transferrin. This receptor is an attractive molecule for the targeted therapy of cancer since it is upregulated on the surface of many cancer types and is efficiently internalized. This receptor can be targeted in two ways: 1) for the delivery of therapeutic molecules into malignant cells or 2) to block the natural function of the receptor leading directly to cancer cell death.Scope of review In the present article we discuss the strategies used to target the TfR for the delivery of therapeutic agents into cancer cells. We provide a summary of the vast types of anti-cancer drugs that have been delivered into cancer cells employing a variety of receptor binding molecules including Tf, anti-TfR antibodies, or TfR-binding peptides alone or in combination with carrier molecules including nanoparticles and viruses.Major conclusions Targeting the TfR has been shown to be effective in delivering many different therapeutic agents and causing cytotoxic effects in cancer cells in vitro and in vivo.General significance The extensive use of TfR for targeted therapy attests to the versatility of targeting this receptor for therapeutic purposes against malignant cells. More advances in this area are expected to further improve the therapeutic potential of targeting the TfR for cancer therapy leading to an increase in the number of clinical trials of molecules targeting this receptor. This article is part of a Special Issue entitled Transferrins: molecular mechanisms of iron transport and disorders.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.bbagen.2011.07.016

Cites

232 of 232 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • A variety of studies confirmed an improved anti-cancer drug uptake upon conjugation to a TfR monoclonal antibody.

    “In fact, a variety of studies confirmed an improved anti-cancer drug uptake upon conjugation to a TfR monoclonal antibody [101,102,103].”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 3

  1. [42]Mayers GL Raghavan D Hitt S Glaves D Transferrin-gemcitabine conjugate: application to chemotherapy Proceedings of the American Association for Cancer Research 89 New Orleans, Louisiana, USA 1998 63
  2. [75]Kircheis R Schuller S Brunner S Ogris M Heider KH Zauner W Wagner E Polycation-based DNA complexes for tumor-targeted gene delivery in vivo J Gene Med 1 1999 111 120 10738575
  3. [184]Eavarone DA Yu X Bellamkonda RV Targeted drug delivery to C6 glioma by transferrin-coupled liposomes J Biomed Mater Res 51 2000 10 14 10813739

Cited by

Sorted by citations

Authors
Daniels, T. R., Bernabeu, E., Rodríguez, J. A., Patel, S., Kozman, M., Chiappetta, D. A., Holler, E., Ljubimova, J. Y., Helguera, G., & Penichet, M. L.
Affiliations
  • Consejo Nacional de Investigaciones Científicas y Técnicas (AR)
  • University of California, Los Angeles (US)
  • Cedars-Sinai Medical Center (US)
Corresponding author
  • Helguera, Gustavo
  • Penichet, Manuel L.
Venue
Biochimica et Biophysica Acta (BBA) - General Subjects
Publisher
Elsevier BV
Published
2012-03
Volume
1820
Issue
3
Pages
291-317
ISSN
0304-4165 (ISSN-L)
OpenAlex
W2027437657
Cited by
807
References
232
Citations by year
2026: 37 · 2025: 50 · 2024: 69 · 2023: 55 · 2022: 57 · 2021: 65 · 2020: 69 · 2019: 75 · 2018: 64 · 2017: 52 · 2016: 59 · 2015: 55 · 2014: 39 · 2013: 47 · 2012: 14
FWCI
1.91
Type
journal article
Language
en
Open access
Locations
  • Biochimica et Biophysica Acta (BBA) - General Subjects (publishedVersion)
  • PubMed (publishedVersion)
  • Conicet (publishedVersion, other-oa)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • CONICET Digital (CONICET) (submittedVersion, cc-by-nc-nd)
Funders
  • NIH/NCI (R01CA136841, R01CA107023, R01CA123495, R01CA57152, U01CA151815, K01CA138559)
  • Howard Hughes Medical Institute Gilliam Fellowship
  • Whitcome Fellowship of the Molecular Biology Institute at UCLA
  • National Agency for Promotion of Science and Technology (ANPCyT-FONARSEC PICT-PRH 2008-00315)
Topics
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Keywords
transferrin receptor, targeted cancer therapy, receptor-mediated drug delivery, transferrin, nanoparticles, viral vectors, iron absorption, cancer cell death
MeSH terms
Antibodies, Monoclonal, Antineoplastic Agents, Carrier Proteins, Genetic Vectors, Humans, Iron, Neoplasms, Receptors, Transferrin, Drug Delivery Systems, Apoptosis, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review